- Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic Semaglutide The Hindu
- Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment NDTV
- A blockbuster unleashed: What happens when a big fat business explodes? The Economic Times
- ‘Price no challenge, mindset is’: Novo Nordisk eyes next-gen anti-obesity drugs as generics enter market ThePrint
- Obesity bet may drive focus on chronic segment: Alkem Labs ET Pharma
Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic Semaglutide The HinduOzempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment NDTVA blockbuster unleashed: What happens when a big fat business explodes? The Economic Times‘Price no challenge, mindset is’: Novo Nordisk eyes next-gen anti-obesity drugs as generics enter market ThePrintObesity bet may drive focus on chronic segment: Alkem Labs ET Pharma by Soban News (international And National News)